MD Anderson Cancer Center, Department of Leukemia
Welcome,         Profile    Billing    Logout  
 17 Trials 
16 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Verstovsek, Srdan
SURPASS ET, NCT04285086: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Active, not recruiting
3
174
Canada, Japan, US, RoW
Ropeginterferon alfa-2b, P1101, Anagrelide
PharmaEssentia, Medpace, Inc., EPS International, Brightech International
Essential Thrombocythemia
11/24
12/25
MYLOX-1, NCT04679870: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
Jain, Nitin
NCT03054896: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Recruiting
2
67
US
Venetoclax, Venclexta, DA-EPOCH-R, R-CHOP
Dana-Farber Cancer Institute, Genentech, Inc.
Richter Syndrome
12/24
12/27
NCI-2022-07625, NCT05536349: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab, GA101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, Valacyclovir, Allopurinol
M.D. Anderson Cancer Center, Loxo Oncology, Inc., The Leukemia and Lymphoma Society
Leukemia
04/25
04/25
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

Recruiting
1/2
120
US
PBCAR0191, Allogeneic Anti-CD19 CAR T cells, Fludarabine, Cyclophosphamide
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
03/24
06/24
BALLI-01, NCT04150497: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
40
Europe, US
UCART22, CLLS52, Alemtuzumab
Cellectis S.A.
B-cell Acute Lymphoblastic Leukemia
12/23
01/26
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
NCT03319901: Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Recruiting
1/2
82
US
Venetoclax, ABT199, Standard Chemotherapy
Dana-Farber Cancer Institute, AbbVie
Leukemia
04/26
04/27
NCI-2018-02016, NCT03698552: ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
65
US
ADCT-602, ADCT-602 (CN); hLL2-cys-PBD (SY); ADCT602 (CN); ADCT 602 (CN); hLL2-cys-SG3249 (SY); ; ADC ADCT-602
M.D. Anderson Cancer Center, National Cancer Institute (NCI), ADC Therapeutics S.A.
Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
12/25
12/25
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
06/27
NCT05275504: Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting
1
37
US
TT-01488
TransThera Sciences (Nanjing), Inc.
B-Cell Malignancies
09/22
04/23
NIMBLE, NCT04865419: Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Terminated
1
46
Europe, US, RoW
AZD0466, Voriconazole
AstraZeneca
Haematological Malignancies
08/23
08/23
NCT05961696: A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Withdrawn
1
22
US
Mosunetuzumab, RO7030816
M.D. Anderson Cancer Center, Genentech, Inc.
Refractory B-cell Acute Lymphoblastic Leukemia
10/23
10/23
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
110
US
AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
Allred, Sheri L
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
CIRLL study, NCT03420183: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Recruiting
1b
156
US
Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib
Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM)
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
04/19
12/22

Download Options